To describe patient and prescriber characteristics and factors associated with utilization of romosozumab in Denmark.MethodsThis registry‑based Danish retrospective cohort study comprised females aged ≥ 50 receiving osteoporosis medication from September 2020 − October 2023. Three cohorts were identified: those treated with romosozumab (cohort 1), those with osteoporosis‑related fracture within the last three years treated with other osteoporosis medications (cohort… Continue reading Treatment patterns of #romosozumab in postmenopausal women with severe #osteoporosis in Denmark: findings from the ROmosozumab in Scandinavia real-world Evidence Study (ROSES)
Tag: osteoporosis
#LEVOTHYROXINE USE AND #BONE LOSS IN #EUTHYROID #OLDER ADULTS: A LONGITUDINAL ANALYSIS FROM BALTIMORE LONGITUDINAL STUDY OF AGING | S3B-SPMS-1
Purpose: Levothyroxine (LT4) is the second most commonly prescribed medication in older adults. Frank hyperthyroidism accelerates bone turnover and even subclinical hyperthyroid has been associated with increased fracture risk. Data indicates that a significant proportion of thyroid hormone prescriptions may be given to older adults without hypothyroidism raising concerns about subsequent relative excess of thyroid… Continue reading #LEVOTHYROXINE USE AND #BONE LOSS IN #EUTHYROID #OLDER ADULTS: A LONGITUDINAL ANALYSIS FROM BALTIMORE LONGITUDINAL STUDY OF AGING | S3B-SPMS-1
Osteoporosis Medication Use After Hip Fracture in U.S. Patients Between 2002 and 2011
ABSTRACTHip fractures are common, morbid, costly, and associated with subsequent fractures. Historically, postfracture osteoporosis medication use rates have been poor, but have not been recently examined in a large-scale study. We conducted a retrospective, observational cohort study based on U.S. administrative insurance claims data for beneficiaries with commercial or Medicare supplemental health insurance. Eligible participants… Continue reading Osteoporosis Medication Use After Hip Fracture in U.S. Patients Between 2002 and 2011
Comparisons Between Different Anti-osteoporosis Medications on Postfracture Mortality: A Population-Based Study
Osteoporosis is becoming a global epidemic in aging societies. Anti-osteoporotic medications can prevent fractures, and their pleiotropic effect on mortality is interesting but not well compared among each other.ObjectiveTo provide real-world evidence on the pleiotropic effect of different anti-osteoporotic medications on all-cause mortality, stratified by fracture site, sex, and age.MethodsThis longitudinal population-based postfracture cohort study,… Continue reading Comparisons Between Different Anti-osteoporosis Medications on Postfracture Mortality: A Population-Based Study
Air pollution and decreased bone mineral density among Women’s Health Initiative participants
BackgroundOsteoporosis heavily affects postmenopausal women and is influenced by environmental exposures. Determining the impact of criteria air pollutants and their mixtures on bone mineral density (BMD) in postmenopausal women is an urgent priority.MethodsWe conducted a prospective observational study using data from the ethnically diverse Women's Health Initiative Study (WHI) (enrollment, September 1994–December 1998; data analysis,… Continue reading Air pollution and decreased bone mineral density among Women’s Health Initiative participants
Simvastatin therapy in higher dosages deteriorates bone quality: Consistent evidence from population-wide patient data and interventional mouse studies
BackgroundCombining mouse experiments with big data analysis of the Austrian population, we investigated the association between high-dose statin treatment and bone quality.MethodsThe bone microarchitecture of the femur and vertebral body L4 was measured in male and ovariectomized female mice on a high-fat diet containing simvastatin (1.2 g/kg). A sex-specific matched big data analysis of Austrian health… Continue reading Simvastatin therapy in higher dosages deteriorates bone quality: Consistent evidence from population-wide patient data and interventional mouse studies
The effect of calcium supplementation in people under 35 years old: A systematic review and meta-analysis of randomized controlled trials
The effect of calcium supplementation on bone mineral accretion in people under 35 years old is inconclusive. To comprehensively summarize the evidence for the effect of calcium supplementation on bone mineral accretion in young populations (≤35 years).Methods:This is a systematic review and meta-analysis. The Pubmed, Embase, ProQuest, CENTRAL, WHO Global Index Medicus, Clinical Trials.gov, WHO… Continue reading The effect of calcium supplementation in people under 35 years old: A systematic review and meta-analysis of randomized controlled trials
Association of Lithium Treatment With the Risk of Osteoporosis in Patients With Bipolar Disorder
Importance Osteoporosis, a systemic skeletal disorder associated with substantial morbidity and mortality, may be particularly common among individuals with bipolar disorder. Lithium, a first-line mood-stabilizing treatment for bipolar disorder, may have bone-protecting properties. Objective To evaluate if treatment with lithium is associated with a decrease in risk of osteoporosis among patients with bipolar disorder. Design,… Continue reading Association of Lithium Treatment With the Risk of Osteoporosis in Patients With Bipolar Disorder
#Bone mineral density and bone turnover ten years after a single 5mg dose or two 5-yearly lower doses of #zoledronate in osteopenic older women: an open-label extension of a randomized controlled trial
Intravenous zoledronate reduces fracture risk (5mg at 18mo intervals) and prevents bone loss (doses of 1-5mg for 3 to >5y), but the duration of action of a single 5mg dose and the effects of lower doses beyond 5 years are unknown. We report the second open-label extension (years 5-10) of a 2y randomized, multidose, placebo-controlled, double-blinded… Continue reading #Bone mineral density and bone turnover ten years after a single 5mg dose or two 5-yearly lower doses of #zoledronate in osteopenic older women: an open-label extension of a randomized controlled trial
2 Medical News 